[en] Estrogens are the subject of intensive researches aiming to elucidate their mechanism of action on the various tissues they target and especially on mammary gland and breast cancer. The use of ready-to-use slow releasing devices to administer steroids, especially estrogens, to small experimental animals remains the method of choice in terms of animal well-being and of safety for both the researcher and the animal. In this study, we evaluated and compared, in vitro and in vivo, the release kinetic of estradiol (E2) over sixty days from two different slow-releasing systems: the matrix pellet (MP) and the reservoir implant (RI). We compared the impact of these systems in three E2-sensitive mouse models : mammary gland development, human MCF7 adenocarcinoma xenograft and mouse melanoma progression. The real amount of E2 that is released from both types of devices could differ from manufacturer specifications due to inadequate release for MP and initial burst effect for RI. Compared to MP, the interindividual variability was reduced with RI thanks to a superior control of the E2 release. Depending on the dose-dependent sensitivity of the physiological or pathological readout studied, this could lead to an improvement of the statistical power of in vivo experiments and thus to a reduction of the required animal number. Altogether, our data draw attention on the importance to adequately select the slow-releasing device that is the most appropriated to a specific experiment to better fulfill the 3Rs rule (Replacement, Reduction, Refinement) related to animal welfare and protection.
Disciplines :
Endocrinology, metabolism & nutrition
Author, co-author :
Gérard, Céline ; Université de Liège > R&D Direction : Chercheurs ULiège en mobilité
Gallez, Anne ; Université de Liège > Département des sciences biomédicales et précliniques > Département des sciences biomédicales et précliniques
Dubois, Charline ; Université de Liège > Département des sciences biomédicales et précliniques > Biochimie et physiologie générales, humaines et path.
Drion, Pierre ; Université de Liège > Département des sciences biomédicales et précliniques > GIGA-R:Méth. expér.des anim. de labo et éth. en expér. anim.
Delahaut, Philippe
Quertemont, Etienne ; Université de Liège > Doyen de la Fac. de Psych., Logopédie et Sc. de l'Education
Noël, Agnès ; Université de Liège > Département des sciences cliniques > Labo de biologie des tumeurs et du développement
Pequeux, Christel ; Université de Liège > Département des sciences biomédicales et précliniques > Département des sciences biomédicales et précliniques
Language :
English
Title :
Accurate Control of 17beta-Estradiol Long-Term Release Increases Reliability and Reproducibility of Preclinical Animal Studies.
Publication date :
March 2017
Journal title :
Journal of Mammary Gland Biology and Neoplasia
ISSN :
1083-3021
eISSN :
1573-7039
Publisher :
Kluwer Academic/Plenum Publishers, New York, United States - New York
Favre J et al. Endothelial estrogen receptor {alpha} plays an essential role in the coronary and myocardial protective effects of estradiol in ischemia/reperfusion. Arterioscler Thromb Vasc Biol. 2010;30(12):2562–7.
Arnal JF et al. Lessons from the dissection of the activation functions (AF-1 and AF-2) of the estrogen receptor alpha in vivo. Steroids. 2013;78(6):576–82.
Brisken C, Ataca D. Endocrine hormones and local signals during the development of the mouse mammary gland. Wiley Interdiscip Rev Dev Biol. 2015;4(3):181–95.
Khalid AB, Krum SA. Estrogen receptors alpha and beta in bone. Bone. 2016;87:130–5.
Hevener AL, Clegg DJ, Mauvais-Jarvis F. Impaired estrogen receptor action in the pathogenesis of the metabolic syndrome. Mol Cell Endocrinol. 2015;418(Pt 3):306–21.
Mohammed H et al. Progesterone receptor modulates ERalpha action in breast cancer. Nature. 2015;523(7560):313–7.
Huang B, Warner M, Gustafsson JA. Estrogen receptors in breast carcinogenesis and endocrine therapy. Mol Cell Endocrinol. 2015;418(Pt 3):240–4.
Jia M, Dahlman-Wright K, Gustafsson JA. Estrogen receptor alpha and beta in health and disease. Best Pract Res Clin Endocrinol Metab. 2015;29(4):557–68.
Bachelot T et al. Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study. J Clin Oncol. 2012;30(22):2718–24.
Fontaine C et al. Tamoxifen elicits atheroprotection through estrogen receptor alpha AF-1 but does not accelerate reendothelialization. Am J Pathol. 2013;183(1):304–12.
Abot A et al. The uterine and vascular actions of estetrol delineate a distinctive profile of estrogen receptor alpha modulation, uncoupling nuclear and membrane activation. EMBO Mol Med. 2014;6(10):1328–46.
Adlanmerini M et al. Mutation of the palmitoylation site of estrogen receptor alpha in vivo reveals tissue-specific roles for membrane versus nuclear actions. Proc Natl Acad Sci U S A. 2014;111(2):E283–90.
Gerard C et al. Estetrol is a weak estrogen antagonizing estradiol-dependent mammary gland proliferation. J Endocrinol. 2015;224(1):85–95.
Gerard C et al. Combined estrogenic and anti-estrogenic properties of estetrol on breast cancer may provide a safe therapeutic window for the treatment of menopausal symptoms. Oncotarget. 2015;6(19):17621–36.
Mallepell S et al. Paracrine signaling through the epithelial estrogen receptor alpha is required for proliferation and morphogenesis in the mammary gland. Proc Natl Acad Sci U S A. 2006;103(7):2196–201.
Pequeux C et al. Stromal estrogen receptor-alpha promotes tumor growth by normalizing an increased angiogenesis. Cancer Res. 2012;72(12):3010–9.
Ingberg E et al. Methods for long-term 17beta-estradiol administration to mice. Gen Comp Endocrinol. 2012;175(1):188–93.
Isaksson IM et al. Methods for 17beta-oestradiol administration to rats. Scand J Clin Lab Invest. 2011;71(7):583–92.
Gordon MN et al. Effective oral administration of 17 beta-estradiol to female C57BL/6 J mice through the drinking water. Biol Reprod. 1986;35(5):1088–95.
Levin-Allerhand JA, Sokol K, Smith JD. Safe and effective method for chronic 17beta-estradiol administration to mice. Contemp Top Lab Anim Sci. 2003;42(6):33–5.
Theodorsson A et al. Serum concentrations of 17beta-estradiol in ovariectomized rats during two times six weeks crossover treatment by daily injections in comparison with slow-release pellets. Scand J Clin Lab Invest. 2005;65(8):699–705.
Aulton ME, Taylor KM. Aulton’s Pharmaceutics: the design and manufacture of medicines. 4th ed. Amsterdam, Netherlands: Churchill Livingstone Elsevier; 2013. p. 908.
Strom JO et al. Different methods for administering 17beta-estradiol to ovariectomized rats result in opposite effects on ischemic brain damage. BMC Neurosci. 2010;11:39.
Zalfen AM et al. Controlled release of drugs from multi-component biomaterials. Acta Biomater. 2008;4(6):1788–96.
Blacher S et al. Quantitative assessment of mouse mammary gland morphology using automated digital image processing and TEB detection. Endocrinology. 2016;157(4):1709–16.
Dall G et al. Low dose, low cost estradiol pellets can support MCF-7 tumour growth in nude mice without bladder symptoms. J Cancer. 2015;6(12):1331–6.
Iwakura A et al. Estrogen-mediated, endothelial nitric oxide synthase-dependent mobilization of bone marrow-derived endothelial progenitor cells contributes to reendothelialization after arterial injury. Circulation. 2003;108(25):3115–21.
Vargo-Gogola T, Rosen JM. Modelling breast cancer: one size does not fit all. Nat Rev Cancer. 2007;7(9):659–72.
Strom JO, Theodorsson E, Theodorsson A. Order of magnitude differences between methods for maintaining physiological 17beta-oestradiol concentrations in ovariectomized rats. Scand J Clin Lab Invest. 2008;68(8):814–22.
Abot A et al. The AF-1 activation function of estrogen receptor alpha is necessary and sufficient for uterine epithelial cell proliferation in vivo. Endocrinology. 2013;154(6):2222–33.
Beleut M et al. Two distinct mechanisms underlie progesterone-induced proliferation in the mammary gland. Proc Natl Acad Sci U S A. 2010;107(7):2989–94.
Kang JS et al. Low dose estrogen supplementation reduces mortality of mice in estrogen-dependent human tumor xenograft model. Biol Pharm Bull. 2009;32(1):150–2.
Meng X et al. Dose-dependent toxic effects of high-dose estrogen on renal and cardiac injury in surgically postmenopausal mice. Life Sci. 2011;88(3–4):178–86.
Sflomos G et al. A preclinical model for ERalpha-positive breast cancer points to the epithelial microenvironment as determinant of luminal phenotype and hormone response. Cancer Cell. 2016;29(3):407–22.
Franco NH, Olsson IA. Scientists and the 3Rs: attitudes to animal use in biomedical research and the effect of mandatory training in laboratory animal science. Lab Anim. 2014;48(1):50–60.
Russell WMS, Burch RL. The principles of human experimental technique. London: Methuen; 1959.
